Skip to main content
Changchun Bcht Biotechnology Co. logo

Changchun Bcht Biotechnology Co. — Investor Relations & Filings

Ticker · 688276 ISIN · CNE100005XY6 LEI · 8368000E14LIZR0C4328 Shanghai Stock Exchange Manufacturing
Open in API
Filings indexed 511 across all filing types
Latest filing 2024-11-22 Governance Information
Country CN China
Listing Shanghai Stock Exchange 688276

About Changchun Bcht Biotechnology Co.

http://www.bchtpharm.com

Changchun BCHT Biotechnology Co. is a biopharmaceutical enterprise focused on the research, development, production, and marketing of human vaccines. The company specializes in preventing infectious diseases through innovative biological products. Its primary product portfolio includes the Varicella Vaccine (Live), which maintains a significant market presence, and the Influenza Vaccine (Live, Nasal, Freeze-dried). Additionally, the company produces the Rabies Vaccine for human use and has expanded its pipeline to include a Herpes Zoster vaccine. BCHT Biotechnology emphasizes technological innovation, utilizing advanced platforms for viral culture and purification to ensure product safety and efficacy. The company operates large-scale manufacturing facilities designed to meet international quality standards, aiming to address public health needs through a diverse range of immunization solutions.

Recent filings

Filing Released Lang Actions
长春百克生物科技股份公司监事会议事规则
Governance Information Classification · 100% confidence The document is titled as "监事会议事规则" which translates to "Supervisory Board Meeting Rules". It details the rules, procedures, and governance structure for the supervisory board of the company, including qualifications, duties, meeting protocols, voting procedures, and other governance-related matters. There is no financial data, no report of financial results, no announcement of voting results, no legal proceedings, no capital changes, and no executive changes. The content is focused on internal governance rules and supervisory board operations, which aligns with governance information. The document length is 6480 characters, which is substantive and not a brief announcement or certification. Therefore, the most appropriate classification is Governance Information (CGR).
2024-11-22 Chinese
长春百克生物科技股份公司募集资金管理制度
Governance Information Classification · 95% confidence The document is titled '募集资金管理制度' which translates to 'Fundraising Capital Management System' and details the rules and regulations for the management and use of funds raised by the company. It references relevant laws and regulatory guidelines related to capital raising and fund management, including the use, storage, supervision, and reporting of raised funds. The content is a detailed internal policy or governance document about fundraising capital management rather than a financial report, earnings release, or announcement. It does not contain financial statements or results, nor is it a notice or announcement of a report. It is a governance-related document outlining internal rules and procedures for managing raised capital. Therefore, the most appropriate classification is Governance Information (CGR).
2024-11-22 Chinese
长春百克生物科技股份公司累积投票制实施细则
Governance Information Classification · 95% confidence The document is titled as "累积投票制实施细则" which translates to "Cumulative Voting System Implementation Rules" for the company 长春百克生物科技股份公司. It details the rules and procedures for implementing cumulative voting in the election of directors and supervisors, including voting methods, calculation, and principles for election. There is no financial data, no mention of financial results, no regulatory filings, no announcements of meetings or votes, and no executive or board changes. It is a governance-related document specifying internal rules for shareholder voting procedures. Therefore, it fits best under Governance Information (CGR). The document length is 2545 characters, which is not a brief announcement but a detailed procedural document, supporting the CGR classification rather than an announcement or regulatory filing.
2024-11-22 Chinese
独立董事提名人声明与承诺（施维）
Board/Management Information Classification · 95% confidence The document is a nomination statement and commitment declaration for an independent director candidate at Changchun Baike Biotechnology Co., Ltd. It details the qualifications, independence criteria, and legal compliance of the nominee. There are no financial statements, earnings data, or report attachments. The content is related to board/management information, specifically about the nomination of a board member. The document length is short (2092 characters), and it is not an announcement of a report publication or a certification. Therefore, the appropriate classification is Board/Management Information (MANG).
2024-11-22 Chinese
独立董事候选人声明与承诺（凌虹）
Regulatory Filings
2024-11-22 Chinese
长春百克生物科技股份公司独立董事工作制度
Governance Information Classification · 95% confidence The document is a detailed internal governance document titled '独立董事工作制度' (Independent Director Work System) for 长春百克生物科技股份公司. It outlines the qualifications, duties, appointment, and responsibilities of independent directors, referencing relevant laws, regulations, and stock exchange rules. It includes templates for nomination and declaration statements for independent directors. There is no financial data, earnings information, or report publication announcement. The content is focused on governance practices and internal rules related to board members, specifically independent directors. Therefore, it fits the category of Governance Information (CGR). The document length (13,410 characters) and detailed procedural content further support this classification.
2024-11-22 Chinese

Browse filings by year

6 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.